Anabolic Agents and the Liver: the organ that processes almost everything entering the body

The liver is not simply an organ that “cleans” the blood. It is a complex metabolic center involved in drug biotransformation, protein synthesis, lipid and glucose metabolism, bile production, storage, and homeostasis. For that reason, how an anabolic agent interacts with the liver depends on its chemical structure, route of administration, duration of exposure, and individual susceptibility.

An important distinction is often lost in simplified discussions: an abnormal liver panel does not automatically mean severe liver damage, while nearly normal enzymes do not always exclude a problem. Interpretation requires clinical and biological context.

1. Why some anabolic agents are more problematic for the liver

One of the most important pharmacological differences is between certain 17α-alkylated steroids and non-alkylated testosterone preparations. The structural modification that allows some oral compounds to resist first-pass metabolism increases their bioavailability, but is also associated with a characteristic hepatotoxicity profile. Oxymetholone, stanozolol, methandienone and other 17α-alkylated androgens are classic examples.

By contrast, non-alkylated testosterone given by injection or transdermally is much less associated with the typical drug-induced cholestatic syndrome. That does not mean every injectable preparation is free of hepatic risk, or that route of administration turns a compound into a safe one.

2. Elevated liver enzymes do not automatically mean liver injury

AST and ALT are used to detect cellular injury, but AST can also come from skeletal muscle. In strength sports, very hard training can cause transient rises in AST and sometimes ALT independently of classic drug hepatotoxicity. Therefore, interpreting the statement “transaminases are high” in isolation can be misleading.

GGT, alkaline phosphatase and bilirubin provide different information. A pattern dominated by bilirubin and alkaline phosphatase can suggest cholestasis, while a predominantly hepatocellular pattern suggests another type of injury. In practice, the values need to be interpreted together.

3. Cholestasis: one of the characteristic reactions to certain anabolic agents

Certain androgenic steroids can produce a distinctive form of liver injury known as bland cholestasis. Paradoxically, a patient may have marked jaundice and bilirubin elevation while ALT and alkaline phosphatase are not dramatically increased. Symptoms can include itching, fatigue, nausea, dark urine and jaundice.

This pattern matters because the intensity of jaundice can appear disproportionate to the rise in transaminases. Recovery may be slow even after exposure is stopped, and disappearance of symptoms should not be assumed to mean complete biological recovery.

4. Bilirubin and what it tells us about bile flow

Bilirubin is produced largely from hemoglobin breakdown and is processed by the liver before being excreted in bile. When bile flow is impaired, conjugated bilirubin can rise and cause jaundice and dark urine.

In cholestasis associated with certain anabolic agents, bilirubin may become much more striking than the transaminases. Exclusive monitoring of AST and ALT can therefore miss an important part of the picture.

5. Why 17α-alkylation matters pharmacologically

17α-alkylation changes hepatic metabolism of the molecule and allows it to survive first-pass metabolism more effectively. This pharmacological solution contributes to the oral availability of some compounds, but intensive hepatic handling is also linked to the characteristic risk of cholestasis and other hepatic complications.

It is not correct to turn this into an absolute rule such as “oral equals toxic, injectable equals safe.” Molecular structure, total exposure, duration, co-exposures and individual susceptibility all matter.

6. What can happen with prolonged exposure

Beyond transient enzyme elevations and cholestasis, long-term androgen exposure has been associated with rare vascular lesions such as hepatic peliosis and with hepatic tumors, including hepatocellular adenomas and, more rarely, hepatocellular carcinoma. Risk is not uniform across molecules, and evidence is stronger for some classes and contexts than others.

Peliosis involves blood-filled cavities within the liver and may be asymptomatic or, rarely, produce severe bleeding complications. It illustrates why a liver problem cannot be assessed from transaminases alone.

7. Fatty liver and the confusion between metabolism and hepatotoxicity

Athletes may also have other reasons for abnormal liver markers: visceral obesity, insulin resistance, diet, alcohol, medications, supplements and metabolic liver disease. Not every abnormality that appears during anabolic use is caused exclusively by the anabolic agent.

Sports supplements can also introduce undeclared compounds or combinations that complicate assessment. A complete history of every substance being taken is essential when liver tests become abnormal.

8. Strongman changes how the laboratory results should be interpreted

In Strongman, large amounts of muscular work and sessions with substantial eccentric loading can raise AST and sometimes ALT. Muscle injury releases enzymes that may appear on panels commonly labeled as “liver tests.” A heavily trained athlete therefore should not be interpreted in exactly the same way as a sedentary person.

CK, training history and the trajectory over time can help distinguish a muscular source from true hepatic injury. Jaundice, dark urine, severe itching, significant abdominal pain or major changes in coagulation make the situation substantially more serious and warrant medical evaluation.

9. Which tests are relevant

A reasonable assessment may include AST, ALT, GGT, alkaline phosphatase and total and fractionated bilirubin. Depending on the context, a clinician may request INR or prothrombin time, albumin, a complete blood count, ultrasound and other investigations to assess liver function and the biliary system.

A single value is generally less informative than a trend. Whether values rise, persist, normalize or change together in several directions can be more important than any isolated number.

10. When the problem becomes urgent

Jaundice, very dark urine, severe itching, persistent vomiting, significant abdominal pain, unusual drowsiness, confusion or unusual bleeding should not be treated as simple “side effects of a cycle.” They may signal a hepatic or systemic problem requiring prompt medical assessment.

11. What happens after exposure stops

Many forms of androgen-associated liver injury improve after the offending agent is stopped, but recovery can take weeks or months. With cholestasis, jaundice and itching may persist long after discontinuation. Structural complications such as some tumors or vascular lesions are not guaranteed to reverse simply by eliminating the agent.

12. The myth: “my liver is fine because I feel fine”

The liver can tolerate some forms of injury for a long time without obvious symptoms. Some drug-induced liver injuries also do not cause pain early on. The absence of symptoms is not a liver function test.

For a strength athlete, the rational approach is to compare the substance history with repeated laboratory tests and, when appropriate, imaging. Physical appearance and performance cannot substitute for medical assessment.

13. Conclusion

Anabolic agents do not all have the same hepatic profile. The risk is particularly relevant for certain 17α-alkylated molecules, which can produce cholestasis, while prolonged androgen exposure has also been associated with rare peliosis and hepatic tumors. At the same time, interpretation of a Strongman athlete’s laboratory results must account for the fact that intense muscular work can raise AST and ALT.

The central message is simple: “elevated liver enzymes” and “liver damage” are not synonyms, and “I feel fine” and “my liver is healthy” are not synonyms. Serious pharmacology begins with understanding mechanisms and ends with objective monitoring and medical evaluation when warning signs appear.

Sources and recommended reading

LiverTox, Androgenic Steroids, National Institute of Diabetes and Digestive and Kidney Diseases; Anabolic androgenic steroid-induced liver injury: An update; Endotext, Androgen Physiology, Pharmacology, Use and Misuse; pharmacovigilance literature on drug-induced liver injury and androgen-associated cholestasis.